| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bladder cancer: neoadjuvant is new again
|
Grossman, H Barton
|
|
2011
|
12 |
9 |
p. 830-831
2 p.
|
artikel
|
| 2 |
Cancer Trials
|
Burki, Talha
|
|
2011
|
12 |
9 |
p. 840-
1 p.
|
artikel
|
| 3 |
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
|
Kreimer, Aimée R
|
|
2011
|
12 |
9 |
p. 862-870
9 p.
|
artikel
|
| 4 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial
|
Di Stasi, Savino M
|
|
2011
|
12 |
9 |
p. 871-879
9 p.
|
artikel
|
| 5 |
First-line therapy for CML: nilotinib comes of age
|
Davies, Jeff
|
|
2011
|
12 |
9 |
p. 826-827
2 p.
|
artikel
|
| 6 |
HPV16 and HPV18 genotyping in cervical cancer screening
|
Ronco, Guglielmo
|
|
2011
|
12 |
9 |
p. 831-832
2 p.
|
artikel
|
| 7 |
IMRT guidelines aim to prevent “catastrophic” errors
|
Furlow, Bryant
|
|
2011
|
12 |
9 |
p. 836-
1 p.
|
artikel
|
| 8 |
Legal fallout continues after nuclear testing
|
Holmes, David
|
|
2011
|
12 |
9 |
p. 835-
1 p.
|
artikel
|
| 9 |
Long-term quality of life in prostate cancer
|
Hamdy, Freddie C
|
|
2011
|
12 |
9 |
p. 832-833
2 p.
|
artikel
|
| 10 |
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial
|
Johansson, Eva
|
|
2011
|
12 |
9 |
p. 891-899
9 p.
|
artikel
|
| 11 |
Missing link: inflammation and ovarian cancer
|
Pejovic, Tanja
|
|
2011
|
12 |
9 |
p. 833-834
2 p.
|
artikel
|
| 12 |
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma
|
Doss, Sally
|
|
2011
|
12 |
9 |
p. 837-838
2 p.
|
artikel
|
| 13 |
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
|
Kantarjian, Hagop M
|
|
2011
|
12 |
9 |
p. 841-851
11 p.
|
artikel
|
| 14 |
Off-label prescriptions: patient safety first
|
The Lancet Oncology,
|
|
2011
|
12 |
9 |
p. 825-
1 p.
|
artikel
|
| 15 |
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
|
Gelmon, Karen A
|
|
2011
|
12 |
9 |
p. 852-861
10 p.
|
artikel
|
| 16 |
PARP inhibitors in cancer: moving beyond BRCA
|
Telli, Melinda L
|
|
2011
|
12 |
9 |
p. 827-828
2 p.
|
artikel
|
| 17 |
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
|
Castle, Philip E
|
|
2011
|
12 |
9 |
p. 880-890
11 p.
|
artikel
|
| 18 |
Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study
|
Lin, Hui-Wen
|
|
2011
|
12 |
9 |
p. 900-904
5 p.
|
artikel
|
| 19 |
Slender Threads
|
Ranscombe, Peter
|
|
2011
|
12 |
9 |
p. 839-
1 p.
|
artikel
|
| 20 |
Treatment implications of the emerging molecular classification system for melanoma
|
Romano, Emanuela
|
|
2011
|
12 |
9 |
p. 913-922
10 p.
|
artikel
|
| 21 |
US court reverses gene patent ruling for BRCA1 and BRCA2
|
Brower, Vicki
|
|
2011
|
12 |
9 |
p. 835-
1 p.
|
artikel
|
| 22 |
Use of antineoplastic agents in patients with cancer who have HIV/AIDS
|
Rudek, Michelle A
|
|
2011
|
12 |
9 |
p. 905-912
8 p.
|
artikel
|
| 23 |
Who should be targeted for vaccination against anal cancer?
|
Harper, Diane M
|
|
2011
|
12 |
9 |
p. 828-829
2 p.
|
artikel
|
Tijdschrift beschrijving